The Institute of NeuroPhysiopathology (INP) is a training and research centre of excellence that combines basic and translational research to study neural cell organisation, function and interaction, the molecular and cellular bases of major brain diseases, and to develop innovative cellular and molecular therapeutic strategies.
The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.
Alexandre Astier is starting his thesis on the theme : Molecular characterisation of primary and recurrent low-grade gliomas
Christophe (Team 7), Ivan (Team 6), Emmanuel (Team 8) and Sarah (Team 4) participated in NeuroMAP Day, the first event that brought together researchers, clinicians, engineers, and students alongside patient associations focused on brain and nervous system disorders. During the event organized by NeuroMarseille, they presented the research being conducted in their respective labs to the general public, making scientific dissemination more accessible to a broader audience. Thank you very much for your participation!
Sarah Moyon 's and Emmanuel Nivet 's teams are glad to be present at the 27th Meeting of the French Glial Cell Club.
Congrats to Marine Dos Santos, Nicolas Vermeersch, Naz Şerifoğlu, Ivan Fernandez Bessone and Raphaël Touron for their poster presentation !
We are pleased to announce that our team has obtained a FRM "2024 prematuration" grant for a project in collaboration with BBB team and Vect-Horus.
The funding will start 1st of November for one year and will allow us to pursue our scientific research on MT5-MMP and its role in Alzheimer disease using in this particular project vectorised mimetic peptides as a potential therapeutical approach.
Maud Gratuze (SynapTau team) has been invited to the SNE 2024 in Nice to give a presentation titled "Unveiling the Brain's Chubby Secrets: Disrupted Cholesterol and Lipid Metabolism in Alzheimer's Disease" at a symposium on Alzheimer's disease.
A new article from the GlioME Team has just been published in Cell Death and Disease: SMAC mimetic drives microglia phenotype and glioblastoma immune microenvironment.
Because generation of patient avatar for preclinical therapeutic development is critically needed in neuro-oncology, the GlioME team in collaboration with the PETRA"TECH" platform developed an easy method to generate tumoroids from primary and metastatic brain tumors, including a dedicated 3D spatial analysis workflow for drug development.
Three presentations at the ESMO Congress 2024 (Barcelona, 13–17 September) reported on therapies designed to stimulate or boost the body’s antitumour immune response in the management of aggressive, high-grade gliomas, which typically carry a poor prognosis.
Emeline Tabouret from GlioME Team discussed these data during the proffered paper session – CNS tumours reported here.
The NeuroCyto lab is looking to hire a postdoctoral fellow for an exciting project at the interface of microscopy and neuronal cell biology.
Deadline for application: January 15th, 2023. Starting date (flexible): April 2023.
About the position and project
Alexandre Astier is starting his thesis on the theme : Molecular characterisation of primary and recurrent low-grade gliomas
Christophe (Team 7), Ivan (Team 6), Emmanuel (Team 8) and Sarah (Team 4) participated in NeuroMAP Day, the first event that brought together researchers, clinicians, engineers, and students alongside patient associations focused on brain and nervous system disorders. During the event organized by NeuroMarseille, they presented the research being conducted in their respective labs to the general public, making scientific dissemination more accessible to a broader audience.
Sarah Moyon 's and Emmanuel Nivet 's teams are glad to be present at the 27th Meeting of the French Glial Cell Club.
Congrats to Marine Dos Santos, Nicolas Vermeersch, Naz Şerifoğlu, Ivan Fernandez Bessone and Raphaël Touron for their poster presentation !
We are pleased to announce that our team has obtained a FRM "2024 prematuration" grant for a project in collaboration with BBB team and Vect-Horus.
The funding will start 1st of November for one year and will allow us to pursue our scientific research on MT5-MMP and its role in Alzheimer disease using in this particular project vectorised mimetic peptides as a potential therapeutical approach.
Maud Gratuze (SynapTau team) has been invited to the SNE 2024 in Nice to give a presentation titled "Unveiling the Brain's Chubby Secrets: Disrupted Cholesterol and Lipid Metabolism in Alzheimer's Disease" at a symposium on Alzheimer's disease.
A new article from the GlioME Team has just been published in Cell Death and Disease: SMAC mimetic drives microglia phenotype and glioblastoma immune microenvironment.
Because generation of patient avatar for preclinical therapeutic development is critically needed in neuro-oncology, the GlioME team in collaboration with the PETRA"TECH" platform developed an easy method to generate tumoroids from primary and metastatic brain tumors, including a dedicated 3D spatial analysis workflow for drug development.
Three presentations at the ESMO Congress 2024 (Barcelona, 13–17 September) reported on therapies designed to stimulate or boost the body’s antitumour immune response in the management of aggressive, high-grade gliomas, which typically carry a poor prognosis.
Emeline Tabouret from GlioME Team discussed these data during the proffered paper session – CNS tumours reported here.
PhD rehearsal
Aix Marseille Université | All rights reserved - Legal notice
